Geode Capital Management LLC Boosts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Geode Capital Management LLC increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 9.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 870,831 shares of the company's stock after buying an additional 76,661 shares during the period. Geode Capital Management LLC owned 1.64% of Stoke Therapeutics worth $10,705,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lynx1 Capital Management LP raised its stake in shares of Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the period. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock valued at $57,177,000 after acquiring an additional 427,447 shares during the period. State Street Corp lifted its stake in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after purchasing an additional 137,145 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock worth $15,686,000 after purchasing an additional 982,451 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Chardan Capital initiated coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating and a $24.00 target price for the company. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, Leerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $21.29.

Stoke Therapeutics Trading Up 2.1 %

STOK stock traded up $0.23 during midday trading on Wednesday, reaching $11.03. 206,963 shares of the company's stock traded hands, compared to its average volume of 745,045. The stock's 50-day moving average is $12.23 and its 200 day moving average is $13.27. The stock has a market cap of $584.23 million, a P/E ratio of -5.25 and a beta of 0.95. Stoke Therapeutics, Inc. has a 52-week low of $4.09 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analysts' expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts expect that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,786 shares of the company's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the transaction, the chief executive officer now directly owns 61,885 shares in the company, valued at $803,886.15. This represents a 9.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the business's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the transaction, the general counsel now directly owns 21,476 shares in the company, valued at $292,288.36. This trade represents a 38.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.